PubMed Health⌕ Search

Biomedical subjects

M Hoyer

Publications and source records attributed to M Hoyer.

7 recordsLinked to original sources
PubMed1995

Interstitial duplication 19p.

We report on a 9-month-old girl with an interstitial duplication of 19p, developmental delay, and multiple anomalies including bifrontal prominence, obtuse frontonasal angle, short columella, additional midline philtral pillar, midline ridge on the tongue, vertical midline ridge at the mental symphysis, and a complex congenital heart defect including severe branch pulmonary artery stenosis, secundum atrial septal defect (ASD), and several ventricular septal defects (VSDs). Use of fluorescent in situ hybridization (FISH) with chromosome 19-specific probes showed a direct duplication of bands 19p13.13 and 19p13.2.

Abnormalities, Multiple↗
PubMed1990

CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease.

The antiparkinsonian efficacy and tolerability of CQA 206-291, a novel ergoline derivative with potent dopamine agonist properties, were studied during 2 months of treatment in 72 parkinsonian patients. In 36 de novo patients (patients who have not previously been treated with levodopa or dopamine agonists), CQA 206-291 was studied in an open design, while in 36 levodopa-treated patients, CQA 206-291 was studied in a randomized, double-blind, parallel-group, placebo-controlled design. CQA 206-291 induced in both groups a significant antiparkinsonian effect with an effective dose range of 5-30 mg/day. The spectrum of adverse events was similar to what is commonly observed with dopamine agonists. Further studies are required to assess the putative therapeutic advantages of CQA 206-291 when compared to other antiparkinsonian drugs.

Aged↗
PubMed1986

Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction.

Culture of human peripheral blood mononuclear cells with purified interleukin 2 (IL-2) results in the induction of a cytotoxic population of cells capable of lysing autologous tumor cells and natural killer (NK) cell resistant tumor cell lines. The current study was undertaken to characterize biological agents which might modulate the induction of lymphokine (IL-2) activated killer (LAK) cells and to optimize culture conditions for LAK cell induction. Preliminary studies were undertaken to characterize optimal time and IL-2 concentration for induction of LAK cell activity. Subsequently, we demonstrated that: (a) LAK cell induction is inhibited at high (2.5 X 10(6)/ml) cell concentrations and this phenomenon is due to the presence of monocytes; (b) depletion of monocytes allows LAK cell induction at 5-10-fold higher cell concentrations without altering the extent or range of LAK-cell activity; (c) interleukin 1 enhances and alpha- and beta-interferons inhibit IL-2 induced proliferation, without altering LAK cell induction; and (d) gamma-interferon alters neither IL-2 induction of proliferation nor LAK cell activity.

Cytotoxicity, Immunologic↗
PubMed1985

[Winter diarrhea].

Winter dysentery is a highly contagious, herd-enzootic disease of cattle, most frequently observed during the winter season. The disease is characterized by a sudden onset of severe diarrhoea, which normally disappears spontaneously within two or three days. The aetiology continues to be obscure, though a virus is a probable causative agent.

Animals↗
PubMed1985

Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.

Recently, gamma-interferon (IFN-gamma) has been shown to be have the capacity to activate macrophages in several murine and human systems. The studies reported here were undertaken to determine the identity of the lymphokine responsible for activation of human monocytes to a tumoricidal state. Macrophage-activating factor (MAF) activity was assessed using a 24-h 51Cr release assay with human monocytes as effector cells and K-562 targets. Stimulated lymphocyte supernatants were produced by stimulation of peripheral blood mononuclear cells with concanavalin A in serum-free media. Interferon was detected in an antiviral assay. Four lines of evidence lead to the conclusion that MAF and IFN-gamma are identical in this system: (a) fractionation of stimulated lymphocyte supernatants by adsorption chromatography, followed by anion or cation exchange chromatography (Mono-S, Mono-Q columns), resulted in nearly identical elution profiles of MAF and IFN activities. All of the individual fractions containing MAF activity were found to contain IFN in amounts corresponding to MAF activity. (b) Monoclonal antibody specific for IFN-gamma neutralized the ability of stimulated lymphocyte supernatants to induce human monocyte tumoricidal activity. This antibody also neutralized the MAF activity of purified IFN-gamma but not alpha-interferon. (c) The biological MAF activity of activated lymphocyte supernatants and IFN-gamma were similar. Dilution versus MAF activity for IFN-gamma and stimulated lymphocyte supernatants exhibited identical slopes. Lymphocyte supernatants and IFN-gamma demonstrated similar MAF activity on three effector cells: monocytes, in vitro-differentiated macrophages, and dexamethasone-differentiated macrophages. (d) Analysis of supernatants produced by five antigen-stimulated human T-cell clones demonstrated coordinate production of MAF and IFN. These results provide compelling evidence for support of the concept that IFN-gamma is the major human lymphokine capable of inducing monocyte-macrophage tumoricidal activity.

Antibodies, Monoclonal↗
PubMedDate not supplied

Fructosamine. A new parameter for diagnosis and metabolic control in diabetic dogs and cats.

Fructosamines are glycated serum proteins that, depending on their life span, reflect glycemic control over the previous 2 to 3 weeks. The nitroblue tetrazolium reduction method adapted to auto analysis appeared to be a practical means to assay fructosamine quickly, economically, and accurately. The upper limit of the reference range is 374 mumol/L in dogs (95% percentile) and 340 mumol/L in cats (95% percentile). Newly diagnosed diabetic dogs and cats that had not undergone previous insulin therapy had significantly higher fructosamine concentrations than nondiabetic animals. In diabetic dogs that were receiving insulin therapy, the fructosamine test reflected the glycemic state far more accurately than did individual blood glucose measurements. Animals with satisfactory metabolic control revealed fructosamine concentrations within the reference range, whereas fructosamine concentrations above 400 mumol/L indicated insufficient metabolic control. On the basis of fructosamine concentrations, cats with a transitory hyperglycemia and cats with diabetes mellitus were differentiated. The fructosamine test is a valuable parameter for the diagnosis and metabolic control of diabetes mellitus in dogs and cats.

Animals↗